HomeFilePharmacology

Pharmacology

View Category

Acute coronary syndromes

Intracoronary Abciximab reduces events in diabetics during PPCI

Diabetic patients have an increased risk of future cardiovascular events after an ST elevation MI. Administration of...
solaci -
Learn More
Antiplatelet

Ticagrelor: Similar to Aspirin in Patients with Stroke or TIA

Ticagrelor might be a more effective antiplatelet therapy than aspirin for the prevention of recurrent stroke and...
solaci -
Learn More
Other

Beta-Blockers for Revascularized Patients: To Prescribe or Not?

This study examines predictors and outcomes associated with the prescription of beta-blockers at discharge after a successful...
solaci -
Learn More
Antiplatelet

Peri-Procedural MI Reduction: Cangrelor or Clopidogrel?

Cangrelor is an intravenous P2Y12 inhibitor approved to reduce peri-procedural ischemic events in patients undergoing PCI that...
solaci -
Learn More
Antiplatelet

Optimal Duration of DAPT: How to Predict Long-Term Events

Courtesy of Dr. Santiago F. Coroleu.   Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel after percutaneous coronary intervention...
solaci -
Learn More
Acute coronary syndromes

No Extra Benefit for Combined Use of Bivalirudin and Transradial Approach

The aim of this meta-analyzis was to study the relation between bivalirudin and access site in patients undergoing...
solaci -
Learn More
Antiplatelet

Ticagrelor Reduces Events in Diabetics with Prior MI

    All studies on diabetics have shown these patients have higher risk rates of thrombotic events. This study...
solaci -
Learn More
Antiplatelet

DAPT after PCI with EES: 6 or 12 Months?

Original Title: 6-Month versus 12-Month Dual-Antiplatelet Therapy Following Long Everolimus-Eluting Stent Implantation. The IVUS-XPL Randomized Clinical Trial. Reference:...
solaci -
Learn More